Clinical trials: Stage IIC Melanoma
Clinical Stage 0 Cutaneous Melanoma AJCC v8, Clinical Stage I Cutaneous Melanoma AJCC v8
PRAME Immunohistochemistry-Guided Slow Mohs Micrographic Surgery for the Treatment of Stage 0 to IIc Cutaneous Melanoma
This clinical trial tests the addition of preferentially expressed antigen in melanoma (PRAME) immunohistochemical (IHC) staining to standard slow Mohs micrographic surgery (SMMS) for guiding tissue removal in patients with stage…
- Conditions
- Clinical Stage 0 Cutaneous Melanoma AJCC v8, Clinical Stage I Cutaneous Melanoma AJCC v8, Clinical Stage II Cutaneous Melanoma AJCC v8
- Trial name
- NCT07258446
- Testing
- Immunohistochemistry Staining Method, Mohs Surgery
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- University of California, Davis
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8
Social Health, Activity Behaviors, and Quality of Life Among Young Adult Cancer Survivors
This longitudinal observational study examines how social health, including social support, social roles, loneliness, social anxiety, and social network characteristics, relates to physical activity, sedentary time, and quality…
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8
- Trial name
- NCT07259304
- Testing
- Medical Device Usage and Evaluation, Quality-of-Life Assessment, Survey Administration
- Where
- 3 sites in United States
- Volunteers
- 173 people
- Sponsor
- University of Southern California
Hereditary Multiple Melanoma, Melanoma (Skin)
Identifying Gene Mutations in Patients With Melanoma and in Families With a History of Hereditary Melanoma
RATIONALE: Identifying gene mutations and other risk factors in patients with melanoma and in families with a history of hereditary melanoma may help doctors identify persons at risk for melanoma and other types of cancer.
- Trial name
- NCT00450593
- Testing
- gene expression analysis, microarray analysis, molecular genetic technique
- Where
- United Kingdom
- Volunteers
- 5,000 people
- Sponsor
- Leeds Cancer Centre at St. James's University Hospital
Cancer
Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor
RATIONALE: When irradiated lymphocytes from a donor are infused into the patient they may help the patient's immune system kill cancer cells.
- Trial name
- NCT00161187
- Testing
- therapeutic allogeneic lymphocytes
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- University of Medicine and Dentistry of New Jersey
Clinical Stage I Cutaneous Melanoma AJCC v8, Clinical Stage IA Cutaneous Melanoma AJCC v8
Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma
This phase I trial investigates the effects of influenza vaccine in treating patients with stage I-IV melanoma. While intramuscular administration of influenza vaccine provides immunization against the influenza virus, giving…
- Conditions
- Clinical Stage I Cutaneous Melanoma AJCC v8, Clinical Stage IA Cutaneous Melanoma AJCC v8, Clinical Stage IB Cutaneous Melanoma AJCC v8, Clinical Stage II Cutaneous Melanoma AJCC v8
- Trial name
- NCT04697576
- Testing
- Ipilimumab, Nivolumab, Pembrolizumab
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Carlo Contreras
Cancer
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
This is a phase III, randomized, double-blind, placebo-controlled, multicenter study of the clinical response to fentanyl sublingual spray as a treatment for breakthrough cancer pain.
- Trial name
- NCT00538850
- Testing
- Fentanyl sublingual spray
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- INSYS Therapeutics Inc
Recurrent Melanoma, Stage IA Melanoma
Vaccine Therapy in Treating HLA-A2 Positive Patients With Melanoma
This randomized pilot phase II trial studies how well vaccine therapy works in treating human leukocyte antigen class 1 histocompatibility, A-2 (HLA-A2) positive patients with melanoma.
- Conditions
- Recurrent Melanoma, Stage IA Melanoma, Stage IB Melanoma, Stage IIA Melanoma
- Trial name
- NCT00003895
- Testing
- HPV 16 E7:12-20, gp100:209-217(210M), laboratory biomarker analysis
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- National Cancer Institute (NCI)
Clinical Stage I Cutaneous Melanoma AJCC v8, Clinical Stage IA Cutaneous Melanoma AJCC v8
The Impact of an Antibiotic (Cefazolin) Before Surgery on the Microbiome in Patients With Stage I-II Melanoma
This phase I trial investigates the impact of cefazolin before surgery on the microbiome in patients with stage I-II melanoma. Antibiotics, such as cefazolin, given at the time of surgery may cause a significant change in the…
- Conditions
- Clinical Stage I Cutaneous Melanoma AJCC v8, Clinical Stage IA Cutaneous Melanoma AJCC v8, Clinical Stage IB Cutaneous Melanoma AJCC v8, Clinical Stage II Cutaneous Melanoma AJCC v8
- Trial name
- NCT04875728
- Testing
- Cefazolin, Resection
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- M.D. Anderson Cancer Center
Melanoma
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
The purpose of this study is to determine how safe and how well POL-103A works in preventing the relapse of melanoma after patients who have undergone surgery.
- Trial name
- MAVIS (NCT01546571)
- Testing
- POL-103A, POL-103A without API
- Where
- 65 sites in United States, Canada
- Volunteers
- 504 people
- Sponsor
- Polynoma LLC
Cutaneous Melanoma, Melanoma
A Vaccine (CDX-1401) With or Without a Biologic Drug (CDX-301) for the Treatment of Patients With Stage IIB-IV Melanoma
This phase II trial studies the effect of a vaccine called CDX-1401 given with or without a biologic drug called CDX-301 in treating patients with stage IIB-IV melanoma.
- Conditions
- Cutaneous Melanoma, Melanoma, Melanoma of Unknown Primary, Mucosal Melanoma
- Trial name
- NCT02129075
- Testing
- DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Recombinant Flt3 Ligand
- Where
- 7 sites in United States
- Volunteers
- 60 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Esophageal Squamous Cell Carcinoma, Advanced Renal Cell Carcinoma
Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program
This phase II trial compares the impact of subcutaneous (SC) nivolumab given in an in-home setting to an in-clinic setting on cancer care and quality of life.
- Conditions
- Advanced Esophageal Squamous Cell Carcinoma, Advanced Renal Cell Carcinoma, Clinical Stage II Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage IIB Cutaneous Melanoma AJCC v8
- Trial name
- NCT06265285
- Testing
- Home Health Encounter, Nivolumab, Patient Monitoring
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Mayo Clinic
Melanoma (Skin)
Studying Tumor Tissue Samples From Patients With Melanoma Who Have Undergone Sentinel Lymph Node Biopsy
RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00897481
- Testing
- gene expression analysis, mutation analysis, diagnostic laboratory biomarker analysis
- Where
- United Kingdom
- Volunteers
- 1,000 people
- Sponsor
- Leeds Cancer Centre at St. James's University Hospital
Stage IIB Melanoma, Stage IIC Melanoma
Neoadjuvant Pembrolizumab in Patients With High Risk, Stage IIB/IIC Cutaneous Melanoma: a Single Arm Proof of Concept Phase IIA Study.
This phase II trial examine whether neoadjuvant PD-1 blockade will achieve a pathological response with manageable toxicity in stage IIB/IIC melanoma.
- Trial name
- NEOSTART (NCT07883759)
- Testing
- Pembrolizumab neoadjuvant treatment, surgery, Adjuvant treatment
- Where
- 2 sites in France
- Volunteers
- 19 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Stage IB Melanoma, Stage IIA Melanoma
Sargramostim or Hypertonic Saline Before Sentinel Lymph Node Biopsy in Treating Patients With Stage IB-II Melanoma
This randomized phase III trial studies sargramostim before sentinel lymph node biopsy to see how well it works compared to hypertonic saline before sentinel lymph node biopsy in treating patients with melanoma.
- Conditions
- Stage IB Melanoma, Stage IIA Melanoma, Stage IIB Melanoma, Stage IIC Melanoma
- Trial name
- NCT01826864
- Testing
- sargramostim, sentinel lymph node biopsy, laboratory biomarker analysis
- Where
- United States
- Sponsor
- Jonsson Comprehensive Cancer Center
Melanoma (Skin)
Vaccine Therapy With or Without Sargramostim in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Colony-stimulating factors such as sargramostim may increase the number of immune cells found in bone marrow or peripheral blood.
- Trial name
- NCT00089193
- Testing
- incomplete Freund's adjuvant, multi-epitope melanoma peptide vaccine, sargramostim
- Where
- 5 sites in United States
- Sponsor
- Craig L Slingluff, Jr
Acute Myeloid Leukemia, Brain Glioblastoma
Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer
This randomized pilot clinical trial studies health care coach support in reducing acute care use and cost in patients with cancer.
- Conditions
- Acute Myeloid Leukemia, Brain Glioblastoma, Estrogen Receptor Negative, Extensive Stage Small Cell Lung Carcinoma
- Trial name
- NCT03154190
- Testing
- Best Practice, Laboratory Biomarker Analysis, Supportive Care
- Where
- United States
- Volunteers
- 128 people
- Sponsor
- Stanford University
Melanoma
Injection Of AJCC Stage IIB, IIC, III And IV Melanoma Patients With A Multi-Epitope Peptide Vaccine Using GM-CSF DNA As An Adjuvant: A Pilot Trial To Assess Safety And Immunity
This is a pilot trial to investigate the use of GM-CSF DNA as an adjuvant for peptide vaccination in patients with metastatic melanoma.
- Trial name
- NCT00580060
- Testing
- GM-CSF DNA, NSC 683472 gp100: 209-217(210M), NSC 699048 Tyrosinase: 368-376(370D)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Malignant Melanoma Stage II
Adjuvant Nivolumab Treatment in Stage II (IIA, IIB, IIC) High-risk Melanoma
Stage II patients with primary surgical treatment of cuMM are often at risk for recurrence of their disease. This risk may be reduced by adjuvant systemic treatment.
- Trial name
- NivoMela (NCT04309409)
- Testing
- Nivolumab
- Where
- 20 sites in Germany
- Volunteers
- 374 people
- Sponsor
- University Hospital, Essen
Melanoma
Immune Responses to Autologous Langerhans-type Dendritic Cells Electroporated With mRNA Encoding a Tumor-associated Antigen in Patients With Malignancy: A Single-arm Phase I Trial in Melanoma
This study is being done to see if the investigators can help the immune system to work against melanoma. A dendritic cell is another type of white blood cell.
- Trial name
- NCT01456104
- Testing
- Langerhans-type dendritic cells (a.k.a. Langerhans cells or LCs)
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Recurrent Melanoma, Stage IA Skin Melanoma
Intravital Microscopy for Identifying Tumor Vessels in Patients With Stage IA-IV Melanoma That is Being Removed by Surgery
This pilot clinical trial studies intravital microscopy for identifying tumor vessels in patients with stage IA-IV melanoma that is being removed by surgery.
- Conditions
- Recurrent Melanoma, Stage IA Skin Melanoma, Stage IB Skin Melanoma, Stage IIA Skin Melanoma
- Trial name
- NCT01886235
- Testing
- Diagnostic Microscopy, Fluorescein Sodium Injection, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Roswell Park Cancer Institute